← Back to Clinical Trials
Recruiting Phase 4 NCT07210125
Implementation and Deliver of Lenacapavir for PrEP in a Community Pharmacy Setting
Trial Parameters
Condition HIV
Sponsor Kelley-Ross & Associates, Inc.
Study Type INTERVENTIONAL
Phase Phase 4
Enrollment 75
Sex ALL
Min Age 18 Years
Max Age N/A
Start Date 2025-09-16
Completion 2027-03-31
Interventions
Lenacapavir long-actingStandard of Care (SOC)
Brief Summary
This is an open-label, single center study to evaluate implementation of a pharmacist-managed delivery of L4P in a community pharmacy setting and the impact of twice-yearly vs. quarterly PrEP visits on STI rates.
Eligibility Criteria
Inclusion Criteria: * 18 years of age or older at the time of screening * weight greater than or equal to 35kg * HIV-negative status * Willing to provide informed consent and undergo all required study procedures Exclusion Criteria: * Unknown or positive HIV status * Coadministration of drugs that significantly decreases lenacapavir concentrations according to the FDA package insert * Any participant that do not meet criteria for management under the CDTA